Nvidia shares pop as analysts dismiss AI bubble concerns
Tharimmune, Inc. (NASDAQ:THAR) announced Monday that its Board of Directors has appointed Sireesh Appajosyula as interim Chief Financial Officer. The appointment was made on Friday and will remain in effect until no later than December 31, 2025. The leadership change comes during a period of notable stock momentum, with THAR shares posting a 30.9% return over the past week and 177.5% over the last six months.
According to a statement included in the company’s filing with the Securities and Exchange Commission, Mr. Appajosyula’s previously disclosed employment agreement with Tharimmune remains in effect during his interim tenure.
Tharimmune, a pharmaceutical company incorporated in Delaware, is listed on The Nasdaq Stock Market LLC. The company’s principal executive offices are located in Red Bank, New Jersey.
This information is based on a press release statement included in a recent SEC filing.
In other recent news, Tharimmune, Inc. has raised approximately $545 million through a private placement offering. This move is part of the company’s strategy to fund its digital asset treasury focused on Canton Coin. The private placement involved the sale of common stock and pre-funded warrants to accredited investors, with significant participation from firms like DRW, Liberty City Ventures, ARK Invest, and the Canton Foundation. Tharimmune issued shares at $3.075 each, with the funds expected to support their Canton Coin blockchain strategy. Additionally, Tharimmune has amended its Certificate of Incorporation to increase the number of authorized common shares from 250 million to 1 billion. This amendment was filed with the Secretary of State of Delaware and detailed in a Securities and Exchange Commission filing. These developments highlight Tharimmune’s strategic efforts in expanding its digital asset initiatives and corporate structure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.